We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Port Erin | LSE:PEBI | London | Ordinary Share | IM00B6QH1J21 | ORD 0.0001P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 4.50 | 4.00 | 5.00 | - | 0.00 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
04/10/2013 08:25 | Thx tightfist. Interesting to see PEBI's share price nice and solid, and with another 200,000 shares traded already today, despite both PLE and SUMM coming off their highs. I've corrected two or three calculations in the thread header post which were erroneous re the American stockholdings. | rivaldo | |
30/9/2013 13:26 | Rivaldo, I just sat down and did a spreadsheet exercise to see if this was an attractive alternative approach to increasing my exposure to SUMM whilst adding more diversity, as JM seems to know how to pick them! And have priviledged information sources. For example, I was surprised that after the glowing comments on 28/03 about Gilead, it appears that at least 75% of that holding had been sold three months later. | tightfist | |
30/9/2013 12:40 | Hi tightfist. Cheers for that - but have you got a link to the valuation, or got more detail please? We'll be getting a 30/9/13 valuation from PEBI themselves soon anyway methinks. | rivaldo | |
30/9/2013 12:28 | Rivaldo, "Some kind soul" has worked through the valuation of the 8 holdings >3% on 30/06/2013 and with no trades they are worth about £3,251k at MID prices (up 140% from £1,357k on 30/06/2013). The other 7 shares mentioned in Jim's 28th March statement are on average up 20% over the past three months, which if fully reflected in the remaining holdings figure (and cash left untouched) would give a NAV of about 17.2p and a discount to NAV today of about 13%. Before allowing for Jim's fee in due course. However... It appears there is quite a lot of trading taking place, as Gilead, Celgene and Biogen Idec which were large holdings on 30th March all appear to be heavily sold-down in April-June. Whether other winners (PLE, SUMM) have been part-sold is unknown but is surely unlikely indeed did PEBI take part in the July SUMM placing? :-) Given the diversity of exposure is 13% discount about right? Seems about right to me; I might be tempted in if it widens a little more. | tightfist | |
26/9/2013 21:43 | RNS tonight - Colin Lee (who he?) has continued buying PEBI shares and now has 2,031,890, or 6%. His last declaration 2 weeks ago was at 1,693,250, so he's bought another 338,000 shares in just the last two weeks. He's evidently quite keen. | rivaldo | |
26/9/2013 10:15 | 25K just bought at 15.4p and going for new closing highs. | rivaldo | |
25/9/2013 13:01 | I've further updated the thread header post with more details of holdings. | rivaldo | |
25/9/2013 07:34 | An encouraging early 31k buy at 16.25p plus a few smaller buys have got things moving nicely. | rivaldo | |
24/9/2013 15:03 | Buying at 15.5p now. I've further updated the header. | rivaldo | |
24/9/2013 12:13 | Nice - 129,000 shares just reported as bought at 15p. | rivaldo | |
24/9/2013 10:44 | Thanks for the post reply rivaldo | euclid5 | |
24/9/2013 10:42 | I've updated the thread header post for approximate shareholdings in the more volatile investee companies. | rivaldo | |
24/9/2013 07:54 | 42k just bought at 14.25p, above the published 14p offer price. SUMM continue to climb, and PLE looks to be consolidating nicely. | rivaldo | |
23/9/2013 08:19 | Euclid, I note that SUMM are also up today as well as PLE, so I'd guess that PEBI's NAV is somewhere from 18p-20p. It would be easier if PEBI published the exact numbers of shares held, which they don't AFAICS. At some stage I should convert the 30/6 holdings in cash terms into approximate numbers of shares held (unless some kind soul already has already done these calculations....!). For reference, the gain in APHB to date may be greater than I thought, as the $100k investment was in a Convertible Loan which was at a lower price than I'd realised at first (and it's now converted) - this is from PEBI's finals "The Company has subscribed US$ 100,000 to a 10% Convertible Promissory Note issued by Ampliphi Biosciences Corporation of Seattle, USA ("Ampliphi"). The terms of the Note, at Ampliphi's discretion, allow the principal and accrued interest to be converted into either Common Stock at the rate of US$ 0.20 or, subject to a number of conditions precedent which, if met, allow the principal and accrued interest be converted at a discounted rate of 10% of US$ 0.20." | rivaldo | |
23/9/2013 07:51 | Rivaldo, what do you make the NAV for PEBI now after your note above please? | euclid5 | |
23/9/2013 07:18 | PLE now up to 15p, and buying coming in here at 13.5p, above the published 13.25p offer price. | rivaldo | |
20/9/2013 12:52 | PLE are now up to 13p after today's news, compared to just over 2p at 30th June. That makes PEBI's £166k at 30/6 now worth over £1m. APHB has also tripled since then, i.e this is now worth around £200k compared to £60k at 30/6. SUMM is now 15p compared to 4p at 30/6, i.e now worth around £800k against the 30/6 £212k. ARWR is now $4.75 against $2 at 30/6, i.e £207k is now worth £475k. These are rather big gains compared to a £3.5m m/cap. | rivaldo | |
14/9/2013 14:02 | I will second that - excellent stable of bio stocks and from reading Jim's Cracking the Code a great deal of hard work and skill lies behind his selections. Fully expect to see 20 p plus within next 6 months | lagosboy | |
22/8/2013 13:18 | Two 50,000 sales today at 7.79p, maybe T1ps fund raising cash or maybe not, buying out-stripping the selling with four buys at 8.25p, 8.25p, 8.5p & 9p. I found it very hard to buy myself without paying above the quote. All in all we should be up to a mid-price of 9p shortly (with more to come), fully warranted with rises in PLE & SUMM alone coupled with very significant rises from Arrowhead, AmpliPhi since June. | fastbuck | |
10/8/2013 21:29 | To be fair as Jim doesn't take a fee and keeps the cost of the fund down to its bare bones I think it's not unreasonable to issue Jim more share in lieu of performance. He also doesn't charge the considerable costs of meeting / attending conferences as he is investing his own money along side PEBI. As you say you take your choice but couldn't agree with you more in stating that the current discount to NBV is entirely appropriate, unless you were talking in general terms. Only a small proportion of the funds is in non-quoted shares I understand and these are choosen due to the opportunity without worry of having to sell to please others or fund redemptions. I would suggest these offer further unrecognised upside rather than a reason to discount the NBV Don't get me wrong I am not blind to price, if I see the share price rise to circ 80% of my estimate of NBV I will sell knowing that I`ve made a tidy profit. I have before and I will again. | fastbuck | |
09/8/2013 14:08 | Not sure I like the fact that Jim gets 15% of the increase in NAV issued as shares. He already owns 29.01% of the company. Looks like 30% will be broken at some point leading to compications with takeover panels (unless I am missing something) - there are some complicated ownership issues here with different trusts etc. Management fees could also be introduced in the future. The discount to NAV is entirely appropriate given the illquidity of many holdings (not quoted companies) A nice way to get exposure to this sector but.... | trentendboy | |
09/8/2013 08:33 | totally agree - with recent meteoric rises in ple, Summit, Synergy, Arrowhead valuation gap even wider. | lagosboy | |
05/8/2013 17:14 | Shares down today, someone sold 50000 at 6.5p. I guess a seller that needs the cash as these are worth well over 12p in underlying investments by my rough calculation.Shame the market doesn't reward the company with a premium price to reflect Jim's experience, knowledge and access to private placings. Must be one of the lowest risk investments on the market at this price | fastbuck |
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions